Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891263 | 1.00 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL9965034 | 1.00 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL12390079 | 0.86 | FKBP1A (0.36) | FKBP1A | |
| SCHEMBL362829 | 0.85 | FKBP1A (0.39) | FKBP1A | |
| SCHEMBL2738540 | 0.82 | FKBP1A (0.33) | FKBP1A | |
| SCHEMBL28912320 | 0.82 | FKBP1A (0.30) | FKBP1A | |
| SCHEMBL14361722 | 0.77 | — | — | |
| SCHEMBL14361662 | 0.77 | — | — | |
| SCHEMBL14361645 | 0.77 | — | — | |
| SCHEMBL14361760 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11339139-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | THE ROCKEFELLER UNIVERSITY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-7598247-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-4707491-A | Anticonvulsant γ-thiobutyrolactone derivatives | WASHINGTON UNIVERSITY (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0229007-A1 | Anticonvulsant gamma-thiobutyrolactone derivatives | WASHINGTON UNIVERSITY (US) | 1987-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | JAK2, JAK1, JAK3 | FKBP1A 1600/4885 |
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | CLPP, MPO, SPOUT1 | FKBP1A 4187/4885 |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | FKBP1A 2092/4885 |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | ALPI, TPMT, SLC10A2 | FKBP1A 2780/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | FKBP1A 2092/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | FKBP1A 85/4885 |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | VIP, PTMS, IAPP | FKBP1A 85/4885 |
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | PAICS, MAP2K4, GIPR | FKBP1A 610/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | FKBP1A 3004/4885 |
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | EP300, CREBBP, BPTF | FKBP1A 2548/4885 |
| US-11339139-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | FKBP1A 1077/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | FKBP1A 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.